Juuri julkaistun meta-analyysin mukaan: ”Individuals that received [pharmacogenetically] guided antidepressant treatment were 41% (95% CI: 15% – 74%) more likely to achieve depressive symptom remission relative to their counterparts who received treatment as usual.”[Brown]
Artikkeli analysoi kymmenen satunnaistettua tutkimusta, joissa oli yhteensä 2614 koehenkilöä. Lisäksi analyysi kattaa kolme sokkouttamatonta tutkimusta, joissa on yhteensä 2153 koehenkilöä.
Viime kuussa julkaistiin lisäksi systemaattinen katsaus farmakogenetiikan kustannusvaikuttavuudesta. Masennuksen osalta katsaus toteaa: ”Nine out of 11 articles evaluating antidepressants were found to be cost effective or cost saving.”[Morris]
Yksi katsauksen artikkeleista arvioi: ”Overall 6-month costs were estimated to be $1,948 (SE 611) lower in the tested group.”[Perlis]
[Brown] Brown, Lisa C., et al. ”Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta‐Analysis of Prospective, Controlled Clinical Trials.” Clinical Pharmacology & Therapeutics(2022). https://doi.org/10.1002/cpt.2748
[Morris] Morris, Sarah A., et al. ”Cost effectiveness of pharmacogenetic testing for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines: a systematic review.” Clinical Pharmacology & Therapeutics (2022). https://doi.org/10.1002/cpt.2754
[Perlis] Perlis, Roy H., et al. ”Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity‐score matched study.” Depression and anxiety35.10 (2018): 946-952. https://doi.org/10.1002/da.22742
